FDA Acceptance of Supplemental NDA for CRESTOR by AstraZeneca
The FDA has accepted a supplemental NDA for CRESTOR (rosuvastatin calcium) submitted by AstraZeneca.
Asset / Drug
Drug and asset intelligence for CRESTOR with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Topline Data
July 8, 2026 · N/A
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.